Clinical
RSSArticles
-
PPI Use and Community-acquired Pneumonia Risks
A new study concluded that the previously noted association between proton pump inhibitor use and community-acquired pneumonia is “likely to be due entirely to confounding factors.”
-
High-dose Statins as a Secondary Prevention
Researchers found there was a graded association between intensity of statin therapy and mortality in patients suffering from atherosclerotic cardiovascular disease.
-
USPSTF Updates Guideline on Screening for Lipid Disorders in Adults
New guideline recommends low- to moderate-dose statins in adults 40-75 years of age without a history of cardiovascular disease who present with one or more risk factors and a calculated 10-year cardiovascular disease event risk of ≥ 10%.
-
An Alternating QRS with AV Block?
There is no 12-lead ECG on this patient, which means that our assessment of QRS morphology is limited to this single right-sided MCL-1 monitoring lead.
-
Clinical Briefs
In this section: connecting asthma to obesity; finding the right treatment for uncomplicated gastroesophageal reflux disease; and better blood pressure control.
-
Bezlotoxumab Injection (Zinplava)
Bezlotoxumab neutralizes the effect of toxin B and reduces the rate of recurrence of C. difficile infection.
-
Is Yoga Effective for Treating Asthma?
Although the data on yoga in asthma are only of moderate quality, they suggest that yoga may improve quality of life and asthma symptoms.
-
What Influences ICU Admission?
High ICU utilization hospitals were more likely to use invasive procedures and incurred higher costs than low ICU utilization hospitals with no difference in mortality.
-
Is Anxiety a Risk Factor for Cardiovascular Disease?
Anxiety disorders are associated with an elevated risk of a range of different cardiovascular events including stroke, coronary heart disease, heart failure, and cardiovascular deaths, but it is unclear whether these disorders are causal in nature.
-
Just Two HPV Shots Recommended for Younger Teens
The CDC now recommends that 11- to 12-year-olds receive two doses of HPV vaccine at least six months apart, rather than the previously recommended three doses.